Myeloma News and Research

RSS

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, notes the 2010 Annual Meeting of the American Society for Clinical Oncology (ASCO) marks the first anniversary of the "Cancer Patient Statement of Principles."

4 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

27 May 2010

Disparities exist in bone marrow transplantation

African-Americans and women are less likely than Caucasians and men to undergo bone marrow transplantation to treat cancers of the blood.

24 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

20 May 2010

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

18 May 2010

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies, Inc. today announced financial results for the three and nine months ended March 31, 2010.

18 May 2010

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Keryx Biopharmaceuticals today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Myeloma News and Research

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Patients with transformed lymphoma show positive response to lenalidomide: Research

Disparities exist in bone marrow transplantation

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies third-quarter net loss increases to $5.28M

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

152 research and training grants awarded to researchers at 93 institutions nationwide

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Immunomedics third-quarter revenues increase to $10.7 million

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

CombinatoRx reports $41.3M total revenue for first-quarter 2010

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Latest News